Urology News and Research

Latest Urology News and Research

Pfizer, Mylan enter settlement agreement to resolve generic Detrol LA litigation

Mylan Inc. today announced that it and its subsidiary, Mylan Pharmaceuticals Inc., have entered into a settlement agreement with Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB that will resolve the parties' patent litigation in connection with Mylan Pharmaceuticals' Abbreviated New Drug Application (ANDA) for Tolterodine Tartrate ER capsules, 2 mg and 4 mg, which is the generic version of Pfizer's Detrol LA, indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

7 Sep 2012

Vitamin D supplements have unintended lipid consequences

Correcting vitamin D levels in individuals at risk for cardiovascular disease may have detrimental effects on their lipid profiles, report researchers.

6 Sep 2012

Preliminary research findings from Kessler Foundation’s Ekso device study on SCI

Kessler Foundation has released preliminary research findings from its clinical study of the wearable robotic exoskeletal device, Ekso. Gail Forrest, PhD, assistant director of Human Performance and Engineering Research, presented the Ekso research data on September 3, at the meeting of the Academy of Spinal Cord Injury Professionals at the Rio Suites in Las Vegas. Dr. Forrest directs mobility research at the Foundation, including activity-based locomotor therapy, functional electrical stimulation, and treadmill training with the LokomatPro v6, as well as Ekso.

6 Sep 2012

Exposure to phthalates increases risk of asthma-related airway inflammation in children

Children exposed to diethyl phthalate (DEP) and butylbenzyl phthalate (BBzP)-phthalate chemicals commonly found in personal care and plastic products-have elevated risk of asthma-related airway inflammation, according to researchers at Columbia Center for Children's Environmental Health (CCCEH) at the Mailman School of Public Health.

6 Sep 2012

Targacept plans to pursue development of TC-5214 for overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it plans to pursue development of TC-5214 as a treatment for overactive bladder (OAB).

6 Sep 2012

New strategy for outsmarting cancer through its own social intelligence

In the face of mounting evidence that cancer cells communicate, cooperate and even engage in collective decision-making, biophysicists and cancer researchers at Rice University, Tel Aviv University and Johns Hopkins University are suggesting a new strategy for outsmarting cancer through its own social intelligence.

5 Sep 2012

Brain derived neurotrophic factor level indicates childhood obesity risk

Brain derived neurotrophic factor may play an important role in the development and pathophysiology of childhood obesity, report researchers.

4 Sep 2012

Exercise paves way to healthy old age

Middle-aged people who have a high level of physical fitness have a significantly lower and later incidence of chronic conditions in old age than those who are less fit, report researchers.

3 Sep 2012

Link between sleep apnoea and overactive bladder syndrome in women

Sleep apnoea in women has been linked to overactive bladder syndrome in a new study. The research, presented at the European Respiratory Society's Annual Congress in Vienna, has provided new evidence suggesting a connection between the two conditions.

3 Sep 2012

Incentives can help promote drug abstinence among pregnant women with heroin or cocaine addiction

A "contingency management" approach—offering incentives for negative drug tests—can help promote drug abstinence among pregnant women with heroin or cocaine addiction, reports a study in the September Addictive Disorders & Their Treatment. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

1 Sep 2012

Sophiris announces data from PRX302 transrectal safety study on Benign Prostatic Hyperplasia

Sophiris Bio Inc. today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection.

1 Sep 2012

Astellas Pharma receives FDA approval for Xtandi to treat metastatic CRPC

The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.

1 Sep 2012

Where there’s no smoke, there’s less bladder cancer

Giving up smoking can significantly improve clinical outcomes in patients with urothelial carcinoma of the bladder, report US researchers.

29 Aug 2012

Society for Women's Health Research Board Chair to address NFWL in Tampa

Stressing the importance of urological health and increased funding into women's health research, Lindsey Kerr, MD, Chair of the Society for Women's Health Research (SWHR) Board of Directors and founder and director of the Urologic Wellness Center at Eastern Maine Medical Center will address the National Foundation for Women Legislators (NFWL) in Tampa, Fla. today.

29 Aug 2012

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pfizer Inc. (NYSE: PFE) announced results from a new post-hoc analysis of the EMPHASIS-HF trial showing statistically significant reductions in rates of cumulative heart failure (HF) hospitalisations in patients with HF treated with eplerenone compared with placebo on a background of standard optimal therapy.1 The results were presented at The European Society of Cardiology Congress (ESC) in Munich.

28 Aug 2012

Academic Urology signs new contract with Independence Blue Cross

Academic Urology, the largest urology specialty medical group in Pennsylvania, announced today that it has signed a new contract with Independence Blue Cross (IBC).

27 Aug 2012

Statins reduce pancreatitis risk

Statins reduce the risk for pancreatitis in patients with normal or mildly elevated triglyceride levels, say the authors of a large meta-analysis.

24 Aug 2012

Survival rate for African-American men with prostate cancer now comparable to Caucasians

The routine use of prostate specific antigen (PSA) testing for screening and monitoring prostate cancer has led to early and more sensitive detection of the disease. A new study published in The Journal of Urology- reports that in the "PSA era," survival has improved for patients with newly diagnosed prostate cancer that has spread to the bones or other parts of the body and the disparity between African American and Caucasian men has been resolved.

24 Aug 2012

Study shows how cancer survival rates developed in West Germany

Data from the 1970s and 1980s show that people affected by cancer survived significantly longer in West Germany than cancer patients behind the Iron Curtain.

24 Aug 2012